Impianti SpA (WMPT25) Quote

If we hit $40 million for the quarter, that puts us at 160 Million for the year. That alone should put us at $1.50

Currently: Buy: 310,300, Neutral: 0, Sell: 16,755,895🤪

Well your admitting yourself he is paying for the news....$2500 is nothing to look down on...that is investment.....the news must be important enough to spend that much when these days they can just post on Facebook or Twitter for free. They are paying for formal news.

I’m putting you on ignore. Bye

You have a few things that you are assuming incorrectly.

A CRL from the FDA is a definitive rejection of the application in its current form. The application can be modified and resubmitted.

Referral to the CHM results in a recommendation to accept, reject, or request a

I won't mind 200k more shares under 1 to round off my stack. 
Ready for the long haul here 

I don't think so, but would really be nice.

https://investorshub.advfn.com/uimage/uploads/2025/4/29/[bvbhsettled.png

Unbelievable this is right back at .0033, with another ask wall at .0034

GGB,

I really wonder if Posner and her people are really starting to dig into their records. of if they're sitting down and seriously negotiating a settlement to the case.

I'm still of the belief that their record won't see the light of day, but time will tell. If a se

It's Citadel though so very likely not a retail seller.CDEL is very notorious for such selling.

DMN: Got to run out, won't be back until 16:30?
Making a bet on that gap close, so set Sell @ .0325 and hope to catch it again on a pullback.
JMHO
GLTA

new highs about to hit now.

I wouldn’t short it when it’s down/oversold already,if trend continues(and it most likely will) this is a bear trap and it’s going to $12,short it then when it’s overbought and at trend resistance. Many other tickers are more appealing to short imo,I do realize it’s up 400%+ for the year(that’s why

Granata Bio Acquires Oviva Therapeutics

Granata Bio has acquired Oviva Therapeutics Inc., a women’s health biotech company focused on advancing treatments that address female physiology, with an emphasis on ovarian aging.

Oviva’s lead candidate, OVI-586, is a first-in-c

Well that's cheap - I gave a percentage chance of approval and you are hinding behind not giving one for another AD drug that failed.

The reason a drug/biotech fails doesn't really matter to whether our investments pays off or don't. Surely any sensible investor has a risk view and a

That's the spirit! 😂

$BNCM ✨DELEX is Building a Healthcare Sector Powerhouse! With the Merger Now Complete, DELEX aims to accelerate innovation, drive rapid growth and expand their market presence. 🌐

https://investorshub.advfn.com/uimage/uploads/2025/4/29/yuupabncm-jp.png

Hmmm..but but you joined right after it supposedly completely ended! Idk what's so good about bioamber that you're still here years and 11k post later. Hmmmm, red flag, definitely more suspicious...

$BURU - NUBURU remains committed to navigating its Transformation Plan, which emphasizes the adoption of exponential technologies, including AI and robotics, and innovative solutions which can underpin the Company’ two key business lines. As a part of this plan entering into the fastest growing glob

By the numbers, it's much more likely we don't see a second clock stop because the EMA doesn't need one than because Anavex withdrew its application.

It is for certain that the possibility of AVXL withdrawing its MAA will be 100% off the table if the clock resumes following the first

docsetc 05/01/24 2:30 PM
Post #197,802
Sit tight, do not sell off.

.. Sure @rocco12 you got it! Disgusting stuff right here

$BNCM ✨DELEX is Building a Healthcare Sector Powerhouse! With the Merger Now Complete, DELEX aims to accelerate innovation, drive rapid growth and expand their market presence. 🌐

https://investorshub.advfn.com/uimage/uploads/2025/4/29/yuupabncm-jp.png

stop spamming your garbage here.

Thank you Femike great DD.

Also, I just realized, it may not have been in direct response to me but the question that sparked Julian Beach's response on 'major objections/CHM meetings' I had sent in an inquiry about to the MHRA in February. Almost verbatim, but I referenced the date